Literature DB >> 15390201

Quantitative analysis of plasma cell-free Epstein-Barr virus DNA in nasopharyngeal carcinoma after salvage nasopharyngectomy: a prospective study.

William I Wei1, Anthony P W Yuen, Raymond W M Ng, W K Ho, Dora L W Kwong, Jonathan S T Sham.   

Abstract

BACKGROUND: The quantity of circulating cell-free Epstein-Barr virus (EBV) DNA in patients with nasopharyngeal carcinoma (NPC) managed by radiotherapy has prognostic relevance. We measured the copy number of EBV DNA in patients with early recurrent NPC before and after salvage nasopharyngectomy.
METHODS: Nasopharyngectomy with the maxillary swing approach was performed for 28 patients. Serum blood samples were taken prospectively before nasopharyngectomy and on postoperative day 7. Plasma cell-free EBV DNA copies were measured with a real-time quantitative polymerase chain reaction for the BamHI-W fragment of the EBV genome.
RESULTS: Cell-free EBV DNA was detected in 17 patients before nasopharyngectomy. Surgical resection reduced the copy number of EBV DNA significantly (p = .016). Negative surgical margins achieved during nasopharyngectomy is associated with a zero EBV DNA copy postoperatively (p = .022).
CONCLUSION: Cell-free EBV DNA was detected in 61% of patients with recurrent NPC, and its quantity postoperatively reflects whether the salvage nasopharyngectomy has achieved a negative surgical margin.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15390201     DOI: 10.1002/hed.20066

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  8 in total

Review 1.  Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge.

Authors:  Tao Xu; J Tang; M Gu; L Liu; W Wei; H Yang
Journal:  Curr Oncol       Date:  2013-10       Impact factor: 3.677

2.  Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker.

Authors:  Aparna A Kamat; Mathew Baldwin; Diana Urbauer; Diana Dang; Liz Y Han; Andrew Godwin; Beth Y Karlan; Joe L Simpson; David M Gershenson; Robert L Coleman; Farideh Z Bischoff; Anil K Sood
Journal:  Cancer       Date:  2010-04-15       Impact factor: 6.860

3.  Current management strategy of nasopharyngeal carcinoma.

Authors:  William I Wei; Dora L W Kwong
Journal:  Clin Exp Otorhinolaryngol       Date:  2010-03-30       Impact factor: 3.372

4.  Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.

Authors:  J S Kalpoe; P B Douwes Dekker; J H J M van Krieken; R J Baatenburg de Jong; A C M Kroes
Journal:  J Clin Pathol       Date:  2006-02-17       Impact factor: 3.411

5.  Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence.

Authors:  Ting Shen; Lin-Quan Tang; Dong-Hua Luo; Qiu-Yan Chen; Pei-Jing Li; Dong-Mei Mai; Shan-Shan Guo; Li-Ting Liu; Chao-Nan Qian; Xiang Guo; Mu-Sheng Zeng; Hao-Yuan Mo; Hai-Qiang Mai
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

6.  Prognostic Impact of Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation Therapy.

Authors:  Hao Peng; Rui Guo; Lei Chen; Yuan Zhang; Wen-Fei Li; Yan-Ping Mao; Ying Sun; Fan Zhang; Li-Zhi Liu; Ai-Hua Lin; Jun Ma
Journal:  Sci Rep       Date:  2016-02-29       Impact factor: 4.379

7.  Prognostic value of various subtypes of extracellular DNA in ovarian cancer patients.

Authors:  Katarina Kalavska; Tomas Minarik; Barbora Vlkova; Denisa Manasova; Michaela Kubickova; Andrej Jurik; Jozef Mardiak; Jozef Sufliarsky; Peter Celec; Michal Mego
Journal:  J Ovarian Res       Date:  2018-09-22       Impact factor: 4.234

8.  Effects of oral maintenance chemotherapy and predictive value of circulating EBV DNA in metastatic nasopharyngeal carcinoma.

Authors:  Han Zhou; Tianzhu Lu; Qiaojuan Guo; Yan Chen; Mengwei Chen; Yansong Chen; Yingying Lin; Chuanben Chen; Liqin Ma; Yun Xu; Shaojun Lin; Jianji Pan
Journal:  Cancer Med       Date:  2020-02-23       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.